Stifel Maintains Hold on RxSight, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 89.0%

Neg 89% Neu 0% Pos 0%

Stifel analyst Tom Stephan maintains RxSight (NASDAQ:RXST) with a Hold and lowers the price target from $8 to $7.

Comments

No comments yet. Be the first!